<i id='90908F9F84'><strike id='90908F9F84'><tt id='90908F9F84'><pre id='90908F9F84'></pre></tt></strike></i>
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year
read more
BRENDANSMIALOWSKI/AFPviaGettyImagesAthirdhumancaseofH5birdflutiedtotheongoingU.S.outbreakincattlehas
read more
NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn
read moreAtissuesampleshowingthepresenceofsyphilisSkipVanOrden/CDCviaAPSyphilis,oneoftheoldestinfectionsknown
